טוען...
Immune checkpoint inhibitors in genitourinary malignancies
Although immune-mediated therapies have been used in genitourinary (gu) malignancies for decades, recent advances with monoclonal antibody checkpoint inhibitors (cpis) have led to a number of promising treatment options. In renal cell carcinoma (rcc), cpis have been shown to have benefit over conven...
שמור ב:
| הוצא לאור ב: | Curr Oncol |
|---|---|
| Main Authors: | , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Multimed Inc.
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7194001/ https://ncbi.nlm.nih.gov/pubmed/32368176 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.27.5121 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|